Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology, c4aeb0)
- Development stage
- Unknown
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Duonda (mitoxantrone hydrochloride liposome) is a liposomal formulation of the anthracenedione antineoplastic agent mitoxantrone, developed by CSPC Pharmaceutical Group. It acts as a DNA intercalator and a topoisomerase II inhibitor, leading to DNA strand breaks and inhibition of DNA synthesis. The liposomal encapsulation is designed to improve the pharmacokinetic profile of mitoxantrone, enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect while reducing systemic toxicities, particularly cardiotoxicity, compared to conventional mitoxantrone. It was first approved in China in January 2022 for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and is currently being investigated for other hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).
- Brand names
- Duonda
- Other names
- Mitoxantrone Hydrochloride Liposome InjectionLiposomal Mitoxantrone
02
Targets
DNAPKC (Protein kinase C family)TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology, c4aeb0).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology, c4aeb0).